- Home
- ABSI vs GOSS Comparison
ABSI vs GOSS Comparison
Compare ABSI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- GOSS
- Stock Information
- Founded
- ABSI 2011
- GOSS 2015
- Country
- ABSI United States
- GOSS United States
- Employees
- ABSI N/A
- GOSS N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- GOSS Health Care
- Exchange
- ABSI Nasdaq
- GOSS Nasdaq
- Market Cap
- ABSI 338.0M
- GOSS 347.8M
- IPO Year
- ABSI 2021
- GOSS 2019
- Fundamental
- Price
- ABSI $2.39
- GOSS $2.47
- Analyst Decision
- ABSI Strong Buy
- GOSS Strong Buy
- Analyst Count
- ABSI 5
- GOSS 4
- Target Price
- ABSI $7.98
- GOSS $8.50
- AVG Volume (30 Days)
- ABSI 4.4M
- GOSS 3.1M
- Earning Date
- ABSI 08-12-2025
- GOSS 08-05-2025
- Dividend Yield
- ABSI N/A
- GOSS N/A
- EPS Growth
- ABSI N/A
- GOSS N/A
- EPS
- ABSI N/A
- GOSS N/A
- Revenue
- ABSI $4,138,000.00
- GOSS $40,237,000.00
- Revenue This Year
- ABSI $44.71
- GOSS N/A
- Revenue Next Year
- ABSI $374.26
- GOSS $30.65
- P/E Ratio
- ABSI N/A
- GOSS N/A
- Revenue Growth
- ABSI 27.32
- GOSS N/A
- 52 Week Low
- ABSI $2.01
- GOSS $0.66
- 52 Week High
- ABSI $6.33
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- ABSI 33.33
- GOSS 68.08
- Support Level
- ABSI $2.50
- GOSS $2.38
- Resistance Level
- ABSI $2.73
- GOSS $2.65
- Average True Range (ATR)
- ABSI 0.18
- GOSS 0.15
- MACD
- ABSI -0.04
- GOSS 0.03
- Stochastic Oscillator
- ABSI 1.94
- GOSS 76.67
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.